LAM Therapeutics Market Reached USD 142.8 Million in 2025 With One Licensed Drug and No Second Approval in Twelve Years

Pheonix Research publishes the first sized estimate of the global LAM therapeutics market

The global market for lymphangioleiomyomatosis (LAM) therapeutics was worth USD 142.8 million in 2025, according to a report published by Pheonix Research, and is forecast to reach USD 212.0 million by 2033 — a compound annual growth rate of 5.06 per cent. The report, Global Lymphangioleiomyomatosis Therapeutics Market Report, Size, Share and Forecast 2026–2033, sizes the market from a treated population of 22,550 patients worldwide and prices it against the US National Average Drug Acquisition Cost series for sirolimus.

LAM is a rare, progressive lung disease affecting predominantly women, in which atypical cells proliferate through the lungs and destroy respiratory function. Twelve years after the first regulatory approval, it has exactly one licensed treatment anywhere in the world.

Three approvals, one molecule, and a generic price

Japan approved sirolimus for LAM on 4 July 2014, following an orphan designation notified on 13 September 2012 and an application filed on 21 October 2013. The United States followed on 28 May 2015 with orphan designation, breakthrough therapy designation and priority review. The European Commission authorised Rapamune for sporadic LAM. All three approvals cover the same off-patent mTOR inhibitor.

Pheonix Research prices that molecule at USD 7.0032 per milligram on the US acquisition benchmark for the generic, against USD 30.9294 for the branded reference. At the 1 to 2 milligrams a day that the label and the Japanese low-dose evidence support, the blended spend per treated patient is USD 6,348 a year.

“That single figure describes the commercial problem in this disease better than any pipeline chart,” the report states. “A therapy approved on three continents, taken daily and taken for life, earns less per patient than a single course of most oncology agents.”

Nine trials, 330 patients, one positive result

The report reviews every interventional study registered in LAM and finds nine, with combined enrolment of 330 people. One met its primary endpoint: MILES, the 89-patient trial published in the New England Journal of Medicine, which established sirolimus and stabilised lung function against decline on placebo. Two did not: the resveratrol and nintedanib studies. One was terminated — the Src inhibitor saracatinib, with a completion date of 30 July 2019. One carries a registry status of unknown four years past its primary completion date — the loratadine study LORALAM.

Two of those records are also corrections to the published literature. A widely cited 2025 review in the European Respiratory Review presents saracatinib as completed with results unavailable and LORALAM as active and recruiting. ClinicalTrials.gov records the first as terminated seven years before that review ran, and the second as status unknown since a primary completion date of 30 December 2022 passed without a reported result.

The decisive trial is unreported

MILED, registered as NCT03150914, randomised sixty patients with preserved lung function to 1 mg daily sirolimus or placebo for two years, with a primary endpoint of FEV1 slope. It is led by the University of Cincinnati with the NHLBI, NCATS and the LAM Foundation as collaborators and the University of South Florida as data coordinating centre. Its primary completion date of 30 June 2025 has passed and the registry reads active, not recruiting. The base case of this forecast rests on it; no result has been published.

The report finds that the barrier to running such a trial was never its cost. Sixty patients for two years at the modelled blended spend is USD 761,760 of drug — 0.53 per cent of one year of the market the trial will determine. The barrier is that a positive result expands the treated population without moving the price, and volume at a generic price is not a return.

Thirty years of research is smaller than one year of revenue

Pheonix Research reconstructs the capital stack behind the disease and finds no venture capital and no public listing in it. The LAM Foundation has raised more than USD 38 million since 1995, directed more than USD 19 million of it into research, and estimates that its grants levered a further USD 90 million from other sources — USD 109 million in total, or 0.76 times a single year of the market that research produced. Average annual research spend across thirty years is USD 633,333, which is 0.44 per cent of annual market value.

The largest single public line is not LAM-specific. The Department of Defense Tuberous Sclerosis Complex Research Program records USD 121 million appropriated across FY2002–24, 228 awards, and USD 10 million for FY2026 — roughly USD 5.5 million a year, 8.68 times the foundation’s research spend, and the reason TSC-associated LAM is the better-studied half of the disease.

Forecast range reflects two binary events, not a soft estimate

The report publishes a base case of USD 212.0 million in 2033 at 5.06 per cent, with a range of 0.48 to 12.81 per cent — USD 148.4 million to USD 374.6 million. The upper bound rests on a reimbursement decision for nintedanib in LAM at branded pricing above USD 110,000 a year, following a 30-patient single-arm study that missed its primary endpoint but held lung function stable on treatment. The lower bound reflects continuing generic price erosion and a negative MILED readout.

About Pheonix Research

Pheonix Research is a market intelligence platform built on a live graph of markets, segments and companies, turning signals into role-specific decisions for procurement, strategy and executive teams rather than into quarterly PDFs. This release and the underlying report are published by Pheonix Research at pheonixresearch.com, where the full patient build, price series and assumptions table behind every figure here are available.

About the report

Global Lymphangioleiomyomatosis Therapeutics Market Report, Size, Share and Forecast 2026–2033 runs to thirteen chapters covering market sizing, clinical trial evidence, pipeline analysis, competitive landscape, value chain, technology, regulation, investment activity, market risk and methodology. Every forecast value is computed from a disclosed patient build and a disclosed price series; the assumptions table flags the single widest assumption — that 8 per cent of TSC-associated LAM receives lung-directed therapy — as the model’s largest source of uncertainty.

Editorial analysis: Thirty Years of LAM Research Raised Less Than One Year of the Market It Created — why thirty years of LAM research capital is smaller than one year of the revenue it produced.

Full report: Global Lymphangioleiomyomatosis Therapeutics Market Report, Size, Share and Forecast 2026–2033